ArticleArchives of women's mental health2026
A systematic safety assessment of zuranolone: real-world adverse event analysis from the FAERS database.
Article in Archives of women's mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThis 2023study aims to evaluate the adverse reaction profile of Zuranolone through large-scale analysis of real-world data and to explore its underlying mechanisms, thereby providing complementary evidence for the safe clinical use of Zuranolone.
methodsReports associated with Zuranolone were extracted from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, covering the period from the third quarter (Q3) of 2023 to the first quarter (Q1) of 2025. Signal detection was performed using four distinct methods: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian Confidence Propagation Neural Network (BCPNN), and the Empirical Bayesian Geometric Mean (EBGM).
resultsA total of 464 reports of adverse events (AEs) related to Zuranolone were included in this study. Signal detection analysis revealed that Zuranolone was most significantly associated with AEs in the System Organ Classes (SOCs) of nervous system disorders and psychiatric disorders. Among the frequently reported AEs, those related to central nervous system (CNS) depression were particularly prominent, including somnolence (135 cases), dizziness (101 cases), sedation (35 cases), and tremor (32 cases). The study also identified common psychiatric AEs, including known events such as anxiety, suicidal ideation, depression, insomnia, depressed mood, and perinatal depression, as well as new potential AEs including panic attack, anger, bradyphrenia, intrusive thoughts, tachyphrenia, and decreased interest.
conclusionEnhanced monitoring for AEs related to nervous system disorders and psychiatric disorders is required during the clinical use of Zuranolone.
Indexed as
Identifiers
41618048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.